Could be really useful regorafenib in hepatocarcinoma treatment vs sorafenib?
Hi Jose,
Regorafenib increased overall survival vs placebo in patients with hepatocellular carcinoma who had progressed on sorafenib treatment.
Median overall survival was 10.6 vs 7.8 months. In the phase III RESORCE trial reported in The Lancet, Jordi Bruix, MD, Head of the Barcelona Clinic Liver Cancer Group, University of Barcelona, and colleagues found concluded: “Regorafenib is the only systemic treatment shown to provide the survival benefit in [hepatocellular carcinoma] patients progressing on sorafenib treatment. Future trials should explore combinations of regorafenib with other systemic agents and third-line treatments for patients who fail or who do not tolerate the sequence of sorafenib and regorafenib.”
Best wishes,
Ilya
- Badges
- Science topic